B
Bio-Techne Corporation (TECH)
NMS – Real Time Price. Currency in USD
47.42
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
47.42
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
| Name | Position |
|---|---|
| Dr. Gary J. Latham Ph.D. | VP & CTO |
| Mr. David Clair C.F.A. | VP of Investor Relations & Corporate Development |
| Mr. Gerry Andros | Vice President of Sales and Marketing |
| Mr. James T. Hippel CPA | Executive VP of Finance & CFO |
| Mr. Kim Kelderman | CEO, President & Director |
| Mr. Luca Cicchetti | Managing Director |
| Mr. Martin Wirtz | Senior Vice President of Strategy & Corporate Development |
| Mr. Shane Bohnen | Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer |
| Mr. William A. Geist | President of Protein Sciences Segment |
| Ms. Cheryl Bethune | Senior VP & Chief Human Resources Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 8-K | tech-20260506x8k.htm |
| 2026-05-06 | 10-Q | tech-20260331x10q.htm |
| 2026-02-11 | 8-K | tech-20260209x8k.htm |
| 2026-02-04 | 10-Q | tech-20251231x10q.htm |
| 2025-11-05 | 8-K | tech-20251030x8k.htm |
| 2025-11-05 | 10-Q | tech-20250930x10q.htm |
| 2025-09-19 | DEFA14A | tech014339-defa14a.htm |
| 2025-09-19 | ARS | tech014339-ars.pdf |
| 2025-08-22 | 10-K | tech-20250630x10k.htm |
| 2025-08-06 | 8-K | tech-20250806x8k.htm |